Literature DB >> 17303427

APOBEC-mediated viral restriction: not simply editing?

Rebecca K Holmes1, Michael H Malim, Kate N Bishop.   

Abstract

The APOBEC family of cytidine deaminases inhibit the mobility of diverse retroviruses, retrotransposons and other viruses. Initial reports proposed that these effects were due to the DNA editing capabilities of these enzymes; however, many recent studies have provided evidence suggesting that APOBEC proteins can inhibit these elements by several mechanisms, including editing-dependent and editing-independent processes. Investigating these modes of action and the potential contribution that each one makes to the antiviral activities of various APOBEC proteins is vital if we are to understand how APOBEC proteins protect host genomes from invading nucleic acids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303427     DOI: 10.1016/j.tibs.2007.01.004

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  154 in total

1.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

2.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 3.  Modulation of intracellular restriction factors contributes to methamphetamine-mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages.

Authors:  Xu Wang; Yizhong Wang; Li Ye; Jieliang Li; Yu Zhou; Sinem Sakarcan; Wenzhe Ho
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

5.  Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Authors:  Tobias Paprotka; Narasimhan J Venkatachari; Chawaree Chaipan; Ryan Burdick; Krista A Delviks-Frankenberry; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 6.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

7.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

8.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

9.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.